1:26 Promising New Enzyme Replacement Therapy for Late-Onset Pompe Disease July 17, 2021 • Pompe Disease Content Hub Priya Kishnani, MD, from @DukeMedSchool, discusses the use of #avalglucosidase alfa in late-onset #PompeDisease.
5:15 Safety and Efficacy of New Enzyme Replacement Therapy for Pompe Disease July 17, 2021 • Pompe Disease Content Hub @HaniKushlaf, of @UCNeuroPMR, discusses the #safety and #efficacy of #avalglucosidase alfa in #PompeDisease.
2:15 Newborn Screening: Communication With Parents July 17, 2021 • Pompe Disease Content Hub Dawn Laney, MS, CGC, CCRC, of the Emory Genetic Clinical Trials Center, discusses #communication with parents regarding #newbornscreening.
7:23 Outcomes of Patients With Multiple Myeloma and COVID-19 June 28, 2021 • Multiple Myeloma Content Hub Nikhil Munshi, MD, of @danafarber and @harvardmed discusses management and outcomes of patients with #multiplemyeloma and #COVID19.
4:21 Monitoring Responses in Patients With Late-Stage Multiple Myeloma June 28, 2021 • Multiple Myeloma Content Hub Heinz Ludwig, MD, from Wilhelminen Cancer Research Institute, discusses #monitoring responses in late-stage #multiplemyeloma.
4:29 Use of Aducanumab for Treatment of Alzheimer’s Disease June 16, 2021 • Neurology Charles Bernick, MD, MPH, of @MemoryBrain_UW, discusses #aducanumab and its use for slowing #Alzheimer #progression.
23:03 Diagnostic Principles for TP53-Mutant AML May 11, 2021 • AML Content Hub @JoeKhouryMD of @MDAndersonNews discusses #diagnosis of #AML with TP53 #mutations.
4:00 Patch Testing for Contact Dermatitis May 6, 2021 • Allergy / Immunology Rachel L. Schreiber, MD, from @TeamAllergy discusses #patchtesting for #contactdermatitis.
3:09 ALS: Accelerating Diagnosis and Treatment March 27, 2021 • Neurology Merit E. Cudkowicz, MD, MSc, from @MGHNeurology, discusses new treatment options for patients with #ALS.
3:02 The Addition of Pembrolizumab Improves Survival in Patients With NSCLC Regardless of PD-L1 Expression February 26, 2021 • Oncology 4-year follow-up of KEYNOTE-189: Pembrolizumab + chemotherapy increases PFS and OS regardless of PD-L1 expression #lungcancer #WCLC20 #IASLC
